Chimeron Bio
About Chimeron Bio
Chimeron Bio develops in vivo CAR-T therapies and cancer vaccines using self-amplifying RNA technology that enables the delivery of large RNA payloads and multiple gene expressions. This approach enhances therapeutic potency and gene expression, addressing the need for more effective and personalized cancer treatments.
```xml <problem> Current cancer treatments often lack the specificity needed to target tumor cells effectively, leading to systemic toxicity and limited efficacy, especially for complex or metastatic cancers. Traditional cancer vaccines and immunotherapies struggle to elicit robust and sustained anti-tumor immune responses. </problem> <solution> Chimeron Bio is developing a platform for in vivo CAR-T therapies, immuno-oncology, and cancer vaccines based on self-amplifying RNA (saRNA) technology. Their approach enables the delivery of large RNA payloads and the expression of multiple genes from a single construct, enhancing therapeutic potency and enabling multi-pathway therapeutic interventions. The saRNA platform facilitates targeted delivery and uptake, potentially improving the specificity and reducing off-target effects of cancer treatments. By delivering multiple proteins, Chimeron Bio aims to stimulate a more comprehensive and durable anti-tumor immune response. </solution> <features> - Self-amplifying RNA (saRNA) technology for enhanced and prolonged gene expression - Capability to deliver exceptionally large RNA payloads, accommodating large or multiple proteins - Multi-gene delivery for co-expression of multiple therapeutic proteins - Potential for targeted delivery via customizable envelope and ligand combinations - Development of in vivo CAR-T therapies, cancer vaccines, and immuno-oncology platforms </features> <target_audience> The primary target audience includes researchers and clinicians focused on developing advanced cancer therapeutics, as well as pharmaceutical companies seeking innovative RNA-based technologies for oncology. </target_audience> ```
What does Chimeron Bio do?
Chimeron Bio develops in vivo CAR-T therapies and cancer vaccines using self-amplifying RNA technology that enables the delivery of large RNA payloads and multiple gene expressions. This approach enhances therapeutic potency and gene expression, addressing the need for more effective and personalized cancer treatments.
How much funding has Chimeron Bio raised?
Chimeron Bio has raised 12800000.
- Funding
- 12800000
- Employees
- 12 employees